研究单位：[1]BeiGene[2]California Cancer Associates For Research and Excellence, Ccare Encinitas,Encinitas,California,United States,92024[3]Valkyrie Clinical Trials,Los Angeles,California,United States,90067[4]California Cancer Associates For Research and Excellence, Inc,San Marcos,California,United States,92069[5]Massachusetts General Hospital,Boston,Massachusetts,United States,02114[6]Dana Farber Cancer Institute,Boston,Massachusetts,United States,02215[7]Msk Basking Ridge,Basking Ridge,New Jersey,United States,07920[8]Msk Monmouth,Middletown,New Jersey,United States,07748[9]Msk Bergen,Montvale,New Jersey,United States,07645[10]Msk Commack,Commack,New York,United States,11725[11]Msk Westchester,Harrison,New York,United States,10604[12]Memorial Sloan Kettering Cancer Center Mskcc,New York,New York,United States,10065[13]Msk Nassau,Uniondale,New York,United States,11553[14]Providence Portland Medical Center,Portland,Oregon,United States,97213[15]Oncology and Hematology Care Clinic Westside,Portland,Oregon,United States,97225-9722[16]The University of Texas Md Anderson Cancer Center,Houston,Texas,United States,77030-4009[17]Blacktown Cancer and Haematology Centre,Blacktown,New South Wales,Australia,2148[18]Chris Obrien Lifehouse,Camperdown,New South Wales,Australia,2050[19]Northern Beaches Hospital,Frenchs Forest,New South Wales,Australia,2086[20]Port Macquarie Base Hospital,Port Macquarie,New South Wales,Australia,2444[21]One Clinical Research,Nedlands,Western Australia,Australia,6009[22]St John of God Health Care,Subiaco,Western Australia,Australia,6008[23]Hospital de Amor Barretos,Barretos,Brazil,14784-400[24]Hospital Do Cancer de Londrina,Londrina,Brazil,86015-520[25]Centro Gaucho Integrado de Oncologia Hospital Mae de Deus,Porto Alegre,Brazil,90850-170[26]Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto,Sao Jose do Rio Preto,Brazil,15090-000[27]Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira,Sao Paulo,Brazil,01246-000[28]The Second Hospital of Anhui Medical University,Hefei,Anhui,China,230601[29]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014[30]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071000[31]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150000[32]Henan Cancer Hospital,Zhengzhou,Henan,China,450000[33]Hubei Cancer Hospital,Wuhan,Hubei,China,430079[34]Nantong Tumor Hospital Branch North,Nantong,Jiangsu,China,226000[35]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,215006[36]The First Affiliated Hospital of Nanchang University Branch Xianghu,Nanchang,Jiangxi,China,332000[37]Jining No Peoples Hospital,Jining,Shandong,China,272000[38]Linyi Peoples Hospital,Linyi,Shandong,China,276000[39]Affiliated Zhongshan Hospital of Fudan University,Shanghai,Shanghai,China,200032[40]Shanghai Pulmonary Hospital,Shanghai,Shanghai,China,200433[41]Shanxi Provincial Cancer Hospital,Taiyuan,Shanxi,China,030013[42]Tianjin Medical University Cancer Institute and Hospital,Tianjin,Tianjin,China,300060[43]Taizhou Hospital of Zhejiang,Taizhou,Zhejiang,China,317000[44]Arensia Exploratory Medicine Llc,Tbilisi,Georgia,0112[45]Centro Ricerche Cliniche Di Verona,Verona,Italy,37134[46]Chungbuk National University Hospital,Cheongjusi,Chungcheongbukdo,Korea, Republic of,28644[47]National Cancer Center,Goyangsi,Gyeonggido,Korea, Republic of,10408[48]Seoul National University Bundang Hospital,Seongnamsi,Gyeonggido,Korea, Republic of,13620[49]The Catholic University of Korea, St Vincents Hospital,Suwonsi,Gyeonggido,Korea, Republic of,16247[50]Severance Hospital Yonsei University Health System,Seoul,Seoul Teugbyeolsi,Korea, Republic of,03722[51]Asan Medical Center,Seoul,Seoul Teugbyeolsi,Korea, Republic of,05505[52]Samsung Medical Center,Seoul,Seoul Teugbyeolsi,Korea, Republic of,06351[53]Tengku Ampuan Afzan Hospital,Kuan
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (< 50%).
